Impact diabetes mellitus in patients undergoing percutaneous coronary intervention

Marcelo Angel Abud, Lucio Tiburcio Padilla, Gustavo Omar Pedernera, Pablo Marcelo Spaletra, Pablo Manuel Lamelas, Alfonsina Candiello, Santiago Ordoñez Buzzino, Pablo Damián Mascolo, Jorge Belardi, Fernando Adrián Cura


Background: Diabetes mellitus (DM) has been associated with an increase in adverse outcomes in patients treated with coronaryangioplasty, compared to non-diabetic patients.Objective: To evaluate the risk of major adverse cardiovascular events in diabetic patients, stratified according to the treatment(non-insulin dependent or insulin-dependent), in a population of unselected patients treated with coronary angioplasty.Methods: Registry-based analysis of patients with coronary artery disease undergoing percutaneous coronary interventionfrom March 2009 to June 2018, according presence of DM stratified according to the established treatment for the metabolicdisorder: insulin-dependent DM (ID-DM) and non-insulin dependent DM (NID-DM). An adjusted Cox regression model wasapplied to evaluate the relationship between the diabetic status and the risk of major adverse cardiovascular events.Results: A total of 6313 patients were included (mean follow-up 4.1 ± 1.8 years), with a global prevalence of DM of 22,8% (noninsulindependent DM 19,1%, insulin-dependent DM 3,8%). Diabetic patients showed a higher risk profile, particularly thosewith ID-DM. At the average follow-up, the adjusted risk of MACE was similar between Non-DM patients and the NIR-DMpatients (HR 1,02 [0,81-1,27], p 0.85). In relation to DM-IR patients, it was observed a higher risk of MACE in comparisonto Non-DM (HR 1,73 [1,20-2,49], p 0.003) and NIR-DM (HR 1,65 [1,10-2,48], p 0.015). A significant interaction was observedbetween the diabetic status and the risk of MACE according to the indication of the percutaneous coronary artery intervention(pint 0.045).Conclusions: In our registry of patients undergoing PCI, with long-term follow-up, DM patients had a higher risk of MACE.The risk of MACE was particularly increased in ID-DM patients. However, there were no significant differences in the riskof MACE between DM-NIR and non-DM patients.


NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooledanalysis of 751 population-based studies with 4.4million participants. Lancet 2016;387:1513-30.

American Diabetic Association: National diabetes fact sheet,

diabetes statistics. Available at: http://www.Diabetes.Org/diabetesbasics/statistics.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46.

Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-8.

Ritsinger V, Saleh N, Lagerqvist B, Norhammar A. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. Circ CardiovascInterv 2015;8:e002328.

Aronson D, Edelman ER: Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord 2010;11:75-86.

Martínez SC, Holmes DR. Controversies surrounding percutaneous coronary intervention in the diabetic patient. Expert Rev CardiovascTher 2016;14:633-48.

Chu ZG, Yang ZG, Dong ZH, Zhu ZY, Peng LQ, Shao H, et al.

Characteristics of coronary artery disease in symptomatic type 2 diabetic patients: Evaluation with CT angiography. Cardiovasc Diabetol 2010;9:74.

Ma J, Wang X, Wang Y, Zhao Y, Gao M, Li X. The relationship

between glycated hemoglobin and complexity of coronary artery lesions among older patients with diabetes mellitus. PLoS One 2014 Mar 21;9:e91972.

García-García HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018;137:2635-50.

Preis SR, Pencina MJ, Hwang SJ, D’Agostino RB Sr, Savage PJ, Levy D, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009;120:212-20.

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370

country-years and 2.7 million participants. Lancet 2011;378:31–40.

Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, et al. Diabetes patients requiring glucose-lowering therapyand nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.

Circulation 2008;117:1945–54.

Berry C, Tardif JC, Bourassa MG. Coronary heart disease in

patients with diabetes: part II: recent advances in coronary revascularization. J Am CollCardiol 2007;49:643–56.

Galante M, Konfino J, Ondarsuhu D, Goldberg L, O´Donnell V, Begue C, et al. Principales resultados de la tercera Encuesta Nacional de Factores de Riesgo de enfermedades no transmisibles en Argentina. Rev Argent Salud Pública 2015;6: 22-9

D’Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013;167:575-84.

Norhammar A, Lindback J, Ryden L, Wallentin L, Stenestrand U; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007;93:1577-83.

Pi SH, Rhee TM, Lee JM, Hwang D, Park J, Park TK, et al.

Outcomes in Patients with Diabetes Mellitus According to Insulin

Treatment After Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era. Am J Cardiol 2018;121:1505-11.

Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. ArteriosclerThrombVasc Biol 2012;32:2052-9.

Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635–45.

Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860–7.

Noman A, Balasubramaniam K, Alhous MH, Lee K, Jesudason P, Rashid M, et al. Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. Catheter Cardiovasc Interv. 2017;89:1195-1204.

Konishi Y, Ashikaga T, Sasaoka T, Kurihara K, Yoshikawa S, Isobe M. Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study. J Cardiol 2016;67:241-7.

Bartorelli AL, EgidyAssenza G, Abizaid A, Banning A, Džavík V, Ellis S, et al. One-year clinical outcomes after sirolimus-eluting coronary stent implantation in diabetics enrolled in the worldwide e-SELECT registry. Catheter Cardiovasc Interv 2016;87:52-62.

Wiemer M, Danzi GB, West N, Voudris V, Koning R, Hoffmann S, et al. Drug-eluting stents with biodegradable polymer for the treatment of patients with diabetes mellitus: clinical outcome at 2 years in a large population of patients. Med Devices (Auckl) 2015;8:153-60.

Li N, Yang YG, Chen MH. Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:238.

Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D,Brogan GX Jr, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non ST-segment elevation acute coronary syndrome. Am Heart J 2013;165:918-25.e2.

Conaway DG, O’Keefe JH, Reid KJ, Spertus J, et al. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005;96:363-5.

Arnold SV, Stolker JM, Lipska KJ, Jones PG, Spertus JA, McGuire DK, et al. Recognition of incident diabetes mellitus during an acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2015;8:260-7.

Hasin T, Hochadel M, Gitt AK, Behar S, Bueno H, Hasin Y, et al. Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus. Am J Cardiol 2009;103:772-8.

Ting HH, Chen AY, Roe MT, et al. Delay from symptom onset to hospital presentation for patients with non ST-segment elevation myocardial infarction. Arch Intern Med 2010;170:1834-41.

Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Arch Intern Med 2004;164:1457–63.

Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004;43:585-91.

Fröbert O, Lagerqvist B, Carlsson J, Lindbäck J, Stenestrand U, James SK, et al. Differences in restenosis rate with different drug eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009;53:1660–7.

Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57:1778-83.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxeleluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903–13.

Piccolo R, Pilgrim T, Heg D, Franzone A, Rat-Wirtzler J, Räber L, et al. Comparative effectiveness and safety of new-generation versus early-generation drug-eluting stents according to complexity of coronary artery disease: a patient-level pooled analysis of 6,081 patients. JACC Cardiovasc Interv 2015;8:1657–6.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomized trials. BMJ 2012;345:e5170.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H,Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15.

Full Text


  • There are currently no refbacks.

Licencia Creative Commons
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.

Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020